ROCKWELL MEDICAL,INC. (NASDAQ:RMTI) Files An 8-K Other Events

ROCKWELL MEDICAL,INC. (NASDAQ:RMTI) Files An 8-K Other Events
Item 8.01 Other Events.

Story continues below

On June7, 2018, Rockwell Medical,Inc. (the “Company”) issued a press release updating our shareholders with respect to the Company’s plan to move forward with the commercial planning and launch of Triferic. Attached hereto as Exhibit99.1 and incorporated herein by reference, is a copy of the press release.

Item 9.01 Financial Statements and Exhibits.

(d)Exhibits. The following exhibits are being filed herewith:

EXHIBITINDEX

ExhibitNo.

Description

99.1

Press Release, dated June7, 2018.


ROCKWELL MEDICAL, INC. Exhibit
EX-99.1 2 a18-15016_1ex99d1.htm EX-99.1 Exhibit 99.1   Rockwell Medical Provides Update on Commercial Strategy   Company to Move Forward with Commercialization of Triferic   WIXOM,…
To view the full exhibit click here

About ROCKWELL MEDICAL,INC. (NASDAQ:RMTI)

Rockwell Medical, Inc. (Rockwell) is a biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis. The Company operates through the hemodialysis market segment, which involves the manufacture, sale and distribution of hemodialysis products to hemodialysis clinics, including pharmaceutical, dialysis concentrates, dialysis kits and other ancillary products used in the dialysis process. Its lead branded drug, Triferic is indicated for iron maintenance. Triferic is an iron compound that is delivered to hemodialysis patients through dialysate, replacing the iron loss that occurs during their dialysis treatment. Its generic drug, Calcitriol, is indicated for treating secondary hyperparathyroidism in dialysis patients. It manufactures, sells, delivers and distributes hemodialysis concentrates, along with a range of ancillary products.

An ad to help with our costs